USANA HEALTH SCIENCES INC
No enriched coverage for $USNA in the last 7 days.
No SEC Form 4 filings for $USNA in the last 30 days.
See all $USNA insider activity →USANA Health Sciences (USNA) will release Q3 2026 earnings on Nov. 3, followed by a conference call on Nov. 4. The company develops and sells nutritional supplements, functional foods, and personal care products.
USANA Health Sciences amended its $75 million revolving credit facility with Bank of America, extendable to $200 million, maturing in 2030. The amendment adds EBITDA covenants, increases asset sale limits, and adjusts sale-leaseback restrictions. Management aims to enhance liquidity and flexibility.
USANA HEALTH SCIENCES INC (USNA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. The information reported in Item 2.03 below is incorporated by reference herein. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On September 30, 202
Recent USNA coverage spans earnings and corporate actions.
The announcement sets the timeline for the upcoming earnings, likely prompting modest pre‑market positioning but no immediate price move.
The amendment improves liquidity but adds tighter covenants, likely resulting in modest neutral impact on the stock.
The amendment tightens financial covenants and expands the asset sale basket, potentially increasing financing flexibility but also imposing stricter performance thresholds.
USANA is highlighted as the article's subject.
Earnings call discloses a goodwill impairment and a lowered full-year outlook tied to near-term DTC marketing pressure and Rise execution issues.
AlphAI scores every news story that mentions USNA with an AI model for sentiment and relevance, and aggregates insider trades from USANA HEALTH SCIENCES INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
USANA Health Sciences (USNA) will release Q3 2026 earnings on Nov. 3, followed by a conference call on Nov. 4. The company develops and sells nutritional supplements, functional foods, and personal care products.
1 min readUSANA Health Sciences amended its $75 million revolving credit facility with Bank of America, extendable to $200 million, maturing in 2030. The amendment adds EBITDA covenants, increases asset sale limits, and adjusts sale-leaseback restrictions. Management aims to enhance liquidity and flexibility.
1 min readUSANA HEALTH SCIENCES INC (USNA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. The information reported in Item 2.03 below is incorporated by reference herein. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On September 30, 202
1 min readNature's Sunshine (NYSE:USNA) reported $117M revenue, up 1.9% YoY, missing estimates. Herbalife (NYSE:HLF) reported $1.33B revenue, up 5.4%, beating estimates. Inter Parfums (NASDAQ:IPAR) reported $341M revenue, up 2.1%, beating estimates. All three stocks declined since earnings.
3 min readUSANA (USNA) held its Q2 2026 earnings call. Management said Core Nutritional was stable, with Mainland China showing renewed strength. The company recorded a preliminary $29 million noncash goodwill impairment and $9 million income tax expense on a $19 million pretax loss. USANA ended the quarter with $169 million cash, zero debt, and $20 million free cash flow, and lowered its fiscal 2026 outlook due to HYA DTC marketing and Rise net sales.
6 min readUSANA Health Sciences (NYSE:USNA) reported Q2 updates including a $29 million preliminary non-cash goodwill impairment tied to its Hiya reporting unit and $9 million income tax expense on a $19 million pre-tax loss. Management cited about $30 million to $40 million top-line pressure and $4 million to $5 million margin pressure, plus a Rise packaging disruption. USANA ended with $169 million cash and no debt.
6 min readUsana Health Sciences (USNA) shares fell about 30% after its Aug. 4 Q2 results missed expectations and guidance disappointed. The company reported non-GAAP EPS of $0.07 on about $223M sales, with sales and profit below analyst averages. It also took a $29M goodwill impairment on Hiya, cut 2024 guidance to an $11M loss and lowered sales to $910M from $925M-$1B.
6 min readUSANA Health Sciences (NYSE:USNA) reported Q2 CY2026 sales of $223 million, down 5.4% year on year, missing market expectations and sending the stock down 19.2% to $18.41. The company said full-year revenue guidance is $962.5 million at the midpoint, 1.8% above analysts’ estimates. Non-GAAP EPS was a $0.07 loss, better than consensus.
4 min readUSANA HEALTH SCIENCES INC (USNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. USANA Health Sciences Reports Second Quarter 2026 Results Company Continues Evolution to a Diversified, Omnichannel Health and Wellness Business SALT LAKE CITY, August 4, 2026 (BUSINESS WIRE)—USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fisca
6 min readUSANA Health Sciences (NYSE:USNA) is set to report Q2 earnings Tuesday after the bell. Last quarter, it reported $250.2M revenue, flat YoY, and beat analysts on EBITDA and EPS. For Q2, analysts expect flat YoY revenue, after a 10.8% rise last year. The article cites an average analyst price target of $39 versus $22.11.
3 min read
